Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

Background Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2022-12, Vol.127 (12), p.2198-2206
Hauptverfasser:	Cabeza-Segura, Manuel, Gambardella, Valentina, Gimeno-Valiente, Francisco, Carbonell-Asins, Juan Antonio, Alarcón-Molero, Lorena, González-Vilanova, Arturo, Zuñiga-Trejos, Sheila, Rentero-Garrido, Pilar, Villagrasa, Rosana, Gil, Mireia, Durá, Ana, Richart, Paula, Alonso, Noelia, Huerta, Marisol, Roselló, Susana, Roda, Desamparados, Tarazona, Noelia, Martínez-Ciarpaglini, Carolina, Castillo, Josefa, Cervantes, Andrés, Fleitas, Tania
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1504/1829 692/4028/67/327 Adenocarcinoma Biomedical and Life Sciences Biomedicine Cancer Research Drug Resistance Epidemiology Esophageal cancer Esophageal Neoplasms - genetics Esophageal Neoplasms - therapy Humans Immune checkpoint inhibitors Immune response Immunomodulation Immunotherapy Microenvironments Molecular Medicine Oncology Patient Selection Patients Prospective Studies Retrospective Studies Transcriptomics Tumor microenvironment Tumor Microenvironment - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS)
ISSN:	0007-0920 1532-1827
DOI:	10.1038/s41416-022-02005-z